Jeffry R. Keyes is recorded as CFO at Quantum-Si Inc (QSI) and Board Member at CNS Pharmaceuticals, Inc. (CNSP). The newest filing on record that lists Jeffry R. Keyes as Board Member at CNS Pharmaceuticals, Inc. (CNSP) is dated August 21, 2026. CNS Pharmaceuticals, Inc. reported in an 8-K filed November 21, 2025 that Jeffry R. Keyes was appointed Director, effective November 17, 2025. CNS Pharmaceuticals, Inc. reported in an 8-K filed May 3, 2024 that Jeffry R. Keyes was appointed Director, effective April 30, 2024. The proxy statement of Quantum-Si Inc reports total compensation of $1,656,849 for Jeffry R. Keyes in fiscal 2025, including a base salary of $481,667. Disclosed compensation is on record for 3 fiscal years. Jeffry R. Keyes has spoken on 2 earnings calls across 1 company, most recently for Quantum-Si Inc on August 5, 2025. Quantum-Si Inc is classified in the Medical Devices industry within the Healthcare sector. CNS Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Quantum-Si Inc includes Jeffrey Hawkins (CEO and Board Member), Jonathan M. Rothberg, Ph.D. (CEO), Jonathan Rothberg (CEO, Chairman and Board Member) and 7 others.
“The Company's stockholders elected John Climaco, Jerzy (George) Gumulka, Jeffry R. Keyes, Faith Charles, Bettina Cockroft, and Amy Mahery, each to serve until the 2026 Annual Meeting of Stockholders or until such person's successor is qualified and elected, by the following vote:”
CNS Pharmaceuticals, Inc. Form 8-K, filed November 21, 2025
· Read the filing
“The Company's stockholders elected John Climaco, Jerzy (George) Gumulka, Jeffry R. Keyes, Faith Charles, Bettina Cockroft, and Amy Mahery, each to serve until the 2025 Annual Meeting of Stockholders or until such person's successor is qualified and elected”
CNS Pharmaceuticals, Inc. Form 8-K, filed May 3, 2024
· Read the filing
Jeffry R. Keyes on recent calls
“Now I'll review the details of our operating results for the second quarter of 2025. Revenue in Q2 2025 was $591,000, which consisted of revenue from our platinum line of instruments, consumable kits, and related services.”
“Now I will review the details of our operating results for the fourth quarter and full year 2024. Revenue in Q4 2024 was approximately $1.2 million, which consisted of revenue from our Platinum instrument, consumable kits, and related services.”
